Kiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $30.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price target raised by JPMorgan Chase & Co. from $26.00 to $30.00 in a research report report published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other research analysts have also recently issued reports about the stock. Wedbush reiterated an outperform rating and issued a $30.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, April 23rd. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a d+ rating to a c rating in a report on Thursday, February 29th. Finally, Evercore ISI raised their price target on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an outperform rating in a report on Wednesday, April 24th. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of Buy and an average target price of $31.00.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA opened at $20.08 on Wednesday. Kiniksa Pharmaceuticals has a one year low of $12.69 and a one year high of $22.09. The company has a 50-day moving average of $19.16 and a two-hundred day moving average of $18.11. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 182.56 and a beta of 0.32.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a negative return on equity of 7.26% and a net margin of 2.78%. The firm had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. During the same quarter in the previous year, the business earned ($0.18) earnings per share. The business’s quarterly revenue was up 65.4% compared to the same quarter last year. Analysts anticipate that Kiniksa Pharmaceuticals will post -0.04 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Sanj K. Patel sold 12,742 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the sale, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $377,262.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sanj K. Patel sold 12,742 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the sale, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,109 shares of company stock worth $709,929. 54.23% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Kiniksa Pharmaceuticals by 13.8% in the third quarter. Bank of New York Mellon Corp now owns 146,568 shares of the company’s stock worth $2,546,000 after buying an additional 17,790 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Kiniksa Pharmaceuticals by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 55,047 shares of the company’s stock worth $956,000 after buying an additional 26,002 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth $777,000. Capula Management Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth $892,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth $176,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.